

ASX ANNOUNCEMENT

10 November 2009

Cytopia releases key data on novel vascular disrupting agent CYT997

Cytopia Limited (ASX:CYT) will present data on its Vascular Disrupting Agent (VDA) CYT997 at the forthcoming *Molecular Targets and Cancer Therapeutics Conference* in Boston, Massachusetts. This annual conference is jointly organised by the American Association of Cancer Research, the US National Cancer Institute and the European Organisation for Research and Treatment of Cancer.

Dr Chris Burns, Research Director at Cytopia, will be presenting the poster in the Angiogenesis and Antiangiogenesis Agents poster session on Monday 16 November 2009, 12:30-2:30pm and again from 5:30-7:30pm (US EST), Halls C-D, Hynes Convention Center, Poster A16.

The poster is entitled *Antitumour activity of CYT997: A Phase II vascular disrupting agent administered orally in combination with cisplatin in a colon adenocarcinoma xenograft model*. It outlines data from preclinical studies with CYT997, the company's lead VDA currently in Phase II clinical studies, clearly demonstrating the profound vascular disrupting effects achieved through repeated oral daily dosing of the compound.

"This data demonstrates the broad potential utility of CYT997 as an anticancer agent. The ability to administer CYT997 orally differentiates it from other VDAs in development and allows more flexible dosing regimes than agents which can only be administered intravenously," said Dr Chris Burns, Director of Research of Cytopia.

A large body of preclinical work on CYT997 has also been published in the November edition of the prestigious journal *Molecular Cancer Therapeutics*. This paper details extensive data from a panel of *in vitro* and *in vivo* experiments that carefully describe the compound's dual anti-vascular and cytotoxic properties.

Enquiries:

Mr Andrew Macdonald
Chief Executive Officer
T: +61 3 9926 0403
andrew.macdonald@cytopia.com.au

Dr Chris Burns
Director, Research
T: +61 3 9926 0407
chris.burns@cytopia.com.au

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and California, USA and specialises in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialled in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise with CYT387, a novel oral JAK1/JAK2 inhibitor focused on the treatment of myeloproliferative disorders, cleared by the FDA for the initiation of a Phase I clinical study.

Website: www.cytopia.com.au